K. Albain Surgery still has a role to play in stage III NSCLC D. Waller Surgery still has a role to play in stage III NSCLC J. van Meerbeeck Surgery has no role to play in stage III NSCLC R. Rami-Porta T stage P. Postmus M stage P. Goldstraw Grouping R. Huber Endoscopic management of carcinoma in situ J. Pignon Individual patient data (IPD) meta-analyses in resectable non-small cell lung cancer (NSCLC) W. Weder A surgical approach F. Shepherd Prognostic and predective factors V. Westeel Phase III study comparing pre-operative and peri-operative chemotherapy E. Vallieres S9900 trial of surgery vs neoadjuvant chemotherapy E. Felip Neoadjuvant vs adjuvant vs surgery alone F. Lagerwaard Risk-adapted 4D sterotatic radiotherapy in stage I NSCLC: Early experience with first 300 pts J. Belderbos Sterotatic irradiation G. Scagliotti The role of chemotherapy in stage I A. Gangi Radio frequency J. Belderbos Individual patient data (IPD) meta-analyses (MA) of chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC) H: Choy Optimized radiation P. de Leyn Staging the mediastinum W. Eberhard Is there room for surgery in stage III B? M. Stuschke PCI S. Senan How to minimize the toxicity D. Ball How to select the patients to receive combined treatment R. van Klaveren Imaging for screening J. Vansteenkiste Role of PET in staging and restaging M. Krasnik The role of EBUS in staging and restaging R. Stahel Aggressive approach of mesothelioma P. Van Houtte How to integrate radiation in the therapeutic management of SCLC J. Sculier What is the standard chemotherapy? R. Pirker Chemotherapy and targeted therapy C. Gridelli New avenues for second-line treatment D. Gandara Current therapy of stage IV NSCLC, moving towards personalized medicine T. Mitsudomi Is adenocarcinoma of the lung one disease? J. Soria Should we adapt therapies according to histology, biology... G. Giaccone Is there a rational development of targeted treatment? J. Engelman EGFR mutations F. Ciardiello VEGF-acting drugs M. To Mouse modeling data for lung cancer risk H. Pass Thoracic Neoplasms and Biomarkers in Body Fluids: Where are we? D. Jablons Case report: The role of surgery in early stage A. Turrisi Case report: How to optimize radiation for stage III D. Gandara Case report: Chemotherapy in stage IV